Article

Working Group on Polytrauma of the German Society of Trauma Surgery (DGU). Red-blood-cell to plasma ratios transfused during massive transfusion are associated with mortality in severe multiple injury: a retrospective analysis from the Trauma Registry of the Deutsche Gesellschaft für Unfallchirurgie

Vox Sanguinis (Impact Factor: 3.3). 07/2008; 95(2):112 - 119. DOI: 10.1111/j.1423-0410.2008.01074.x

ABSTRACT Background To test whether an acute transfusion practice of packed red blood cells (pRBC) : fresh-frozen plasma (FFP) 1 : 1 would be associated with reduced mortality in acute bleeding multiply injury.Methods Retrospective analysis using the TR-DGU database (Trauma Registry of the Deutsche Gesellschaft für Unfallchirurgie 2002–2006) on primary admissions with substantial injury (Injury Severity Score > 16) and massive transfusion (> 10 pRBCs). Seven hundred thirteen patients were divided into three groups according to the pRBC : FFP ratio transfused, that is, (i) pRBC : FFP > 1·1; (ii) pRBC : FFP 0·9–1·1 (1 : 1); and (iii) pRBC : FFP < 0·9, and mortality rates were compared.Results Four hundred ninety-seven (69·7%) of patients were male, the mean age was 40·1 (± 18·3) years. Injury characteristics and pathophysiological state upon emergency room arrival were comparable between groups. Out of 713, 484 patients had undergone massive transfusion with pRBC : FFP > 1·1, 114 with pRBC : FFP 0·9–1·1 (1 : 1), and 115 with pRBC : FFP < 0·9 ratios. Acute mortality (< 6 h) rates for pRBC : FFP > 1·1, pRBC : FFP 0·9–1·1 (1 : 1), and pRBC : FFP < 0·9 ratios were 24·6, 9·6 and 3·5% (P < 0·0001), 24-h mortality rates were 32·6, 16·7 and 11·3% (P < 0·0001), and 30-day mortality rates were 45·5, 35·1 and 24·3% (P < 0·001). The frequency for septic complications and organ failure was higher in the pRBC : FFP 0·9–1·1 (1 : 1) group, ventilator days and length of stays for intensive care unit and overall in-hospital were highest in the pRBC : FFP < 0·9 ratio group (P < 0·0005).Conclusions An association between pRBC : FFP transfusion ratios and mortality to favour early aggressive FFP administration was observed. Further investigation is necessary prior to recommending routine 1 : 1 or more aggressive FFP use in exsanguinating patients.

Download full-text

Full-text

Available from: Rolf Lefering, Oct 02, 2014
1 Follower
 · 
211 Views
  • Source
    • "This approach is also intended to minimize exacerbating a dilutional coagulopathy by replacing lost blood with plasma and platelet containing products instead of early and large amounts of crystalloids and RBCs. This approach has been widely studied, and is quickly becoming a common resuscitation approach in severely injured patients [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65]. Lastly in the austere civilian or military situation, the use of fresh whole blood is recommended for those patients who have massive hemorrhage. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Injury is rapidly becoming the leading cause of death worldwide, and uncontrolled hemorrhage is the leading cause of potentially preventable death. In addition to crystalloid and/or colloid based resuscitation, severely injured trauma patients are routinely transfused RBCs, plasma, platelets, and in some centers either cryoprecipitate or fibrinogen concentrates or whole blood. Optimal timing and quantity of these products in the treatment of hypothermic, coagulopathic and acidotic trauma patients is unclear. The immediate availability of these components is important, as most hemorrhagic deaths occur within the first 3-6h of patient arrival. While there are strongly held opinions and longstanding traditions in their use, there are little data within which to logically guide resuscitation therapy. Many current recommendations are based on euvolemic elective surgery patients and incorporate laboratory data parameters not widely available in the first few minutes after patient arrival. Finally, blood components themselves have evolved over the last 30 years, with great attention paid to product safety and inventory management, yet there are surprisingly limited clinical outcome data describing the long term effects of these changes, or how the components have improved clinical outcomes compared to whole blood therapy. When focused on survival of the rapidly bleeding trauma patient, it is unclear if current component therapy is equivalent to whole blood transfusion. In fact data from the current war in Iraq and Afghanistan suggest otherwise. All of these factors have contributed to the current situation, whereby blood component therapy is highly variable and not driven by long term patient outcomes. This review will address the issues raised above and describe recent trauma patient outcome data utilizing predetermined plasma:platelet:RBC transfusion ratios and an ongoing prospective observational trauma transfusion study.
    Biologicals 01/2010; 38(1):72-7. DOI:10.1016/j.biologicals.2009.10.007 · 1.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the severity and complexity of injuries, survival rates among combat casualties are equal to or better than those from civilian trauma. This article summarizes the evidence regarding innovations from the battlefield that contribute to these extraordinary survival rates, including preventing hemorrhage with the use of tourniquets and hemostatic dressings, damage control resuscitation, and the rapid evacuation of casualties via MEDEVAC and the US Air Force Critical Care Air Transport Teams. Care in the air for critically injured casualties with pulmonary injuries and traumatic brain injury is discussed to demonstrate the unique considerations required to ensure safe en route care. Innovations being studied to decrease sequelae associated with complex orthopedic and extremity trauma are also presented. The role and contributions of the Joint Combat Casualty Research Team and the Joint Theater Trauma System are also discussed.
    AACN Advanced Critical Care 01/2010; 21(3):260-76; quiz 278. DOI:10.1097/NCI.0b013e3181e67385
  • [Show abstract] [Hide abstract]
    ABSTRACT: In den letzten Jahren konnte ein verbessertes Verständnis traumaassoziierter Gerinnungsstörungen (traumainduzierte Koagulopathie) durch eine Reihe neuer wissenschaftlicher Erkenntnisse erreicht werden. Neben dem Gewebetrauma scheinen auch Schock und Minderperfusion für die Entwicklung einer Koagulopathie maßgeblich verantwortlich zu sein. Hypoperfusion kann über eine Endothelaktivierung zur Hyperfibrinolyse führen. Additive Effekte wie Hypothermie und Acidose verstärken diese Gerinnungsstörung. Standardgerinnungstests wie Quick-Test und die Bestimmung der aktivierten partiellen Thromboplastinzeit (aPTT) werden zwar häufig zu Therapieentscheidungen herangezogen, sind aber mit Nachteilen behaftet. Die Thrombelastometrie/-graphie scheint den Routinegerinnungtests überlegen zu sein. Da die Prophylaxe der traumainduzierten Koagulopathie einfacher als die Therapie ist, ist eine antizipierende Vorgehensweise notwendig. Während die pathophysiologischen und pharmakologischen Zusammenhänge der geschilderten Therapieoptionen schlüssig sind, fehlt jedoch für die meisten eine evidenzbasierte Bestätigung durch randomisierte, kontrollierte Studien. Zu dem notärztlichen und anästhesiologischen Konzept der „damage control resuscitation“ gehören die Begrenzung der Infusion von kristalloidem und kolloidalem Volumenersatz auf einen mittleren arteriellen Druck (MAP) von ≥65mmHg (höher bei Schädel-Hirn-Trauma), ein aktives Wärmemanagement, die Verhinderung bzw. der Ausgleich einer Acidose auf einen pH>7,2 bzw. ein „base excess“ (BE)≤−6mmol/l sowie die frühzeitige und ausreichende Gabe von gerinnungsaktiven Medikamenten. Da Erythrozyten auch einen beträchtlichen Anteil am Gerinnungsprozess haben, sollten bei massiver, nichtgestillter Blutung Hämoglobin- (Hb-)Werte um 6,2mmol/l (10g/dl) bzw. ein Hämatokrit (HKT) um 30% angestrebt werden. Ein Fibrinogenmangel entwickelt sich bei schweren Polytraumen früh und muss adäquat ausgeglichen werden. Wenn eine Gerinnungstherapie mit gefrorenem Frischplasma (GFP) durchgeführt wird, müssen ausreichende Mengen (20–30ml/kgKG) verabreicht werden, um die Gerinnungsfaktoren entsprechend anzuheben. Prothrombinkomplexpräparate (PPSB) können bei schweren Blutungen zur Optimierung der Thrombingenerierung hilfreich sein. Da eine Hyperfibrinolyse nach schwerem Trauma häufiger ist als bislang angenommen, sollte insbesondere bei kreislaufinstabilen Patienten an den Einsatz eines Antifibrinolytikums gedacht werden. Die Thrombozytenzahl sollten bei blutenden Polytraumata 100.000/µl nicht unterschreiten. Bei thrombopathischer, diffuser Blutung kann die Infusion von Desmopressin (DDAVP) indiziert sein. Rekombinanter aktivierter FaktorVII stellt eine Therapieoption dar, allerdings nur bei strenger Indikationsstellung und wenn oben genannte Maßnahmen zur Optimierung der Gerinnungssituation ergriffen wurden. In recent years a new understanding of trauma-associated hemorrhaging and trauma-induced coagulopathy has been achieved. This coagulopathy is multifactorial with the predominant mechanisms being tissue trauma, shock and hypoperfusion which can lead to hyperfibrinolysis by activation of the endothelium. Routinely tested coagulation parameters, such as prothrombin time and partial thromboplastin time, are frequently employed for decision making but remain problematic as they do not give any information on clot stability, lysis or platelet function. Thrombelastometry seems to be a useful alternative. A pro-active anticipatory approach is required for a successful outcome to be achieved as rescue correction is more difficult than prevention. While the pathophysiological conception of causal relationship of the mentioned therapeutic options is conclusive, an evidence-based validation by randomized controlled studies is mostly lacking. The emergency and anesthesiological concept of damage control resuscitation consists of limiting volume therapy with crystalloids and colloids to reach a mean arterial pressure ≥65mmHg (higher for head injuries), active (re-)warming management, the prevention of a pH≤7.2 and a base excess (BE) ≤−6mmol/l. The early and sufficient application of hemostatic drugs is essential. Because erythrocytes play a substantial role in the coagulation process, hemoglobin (Hb) values of around 6,2mmol/l (10g/dl) and/or a hematocrit of 30% should be strived for when massive non-arrested hemorrhaging occurs. After severe multiple trauma a fibrinogen deficit develops and must be adequately compensated. If coagulation therapy is carried out using fresh frozen plasma sufficient quantities (20–30ml/kgBW) must be administered to correspondingly raise the coagulation factors. Prothrombin complex concentrates can be helpful to optimize thrombin generation during severe hemorrhaging. Because hyperfibrinolysis occurs more often than previously assumed during severe trauma, an anti-fibrinolytic therapy should be used especially for patients with an instable circulation. The platelet count should not go below 100,000/µl when hemorrhaging occurs after multiple trauma. For thrombocytopathic patients with diffuse bleeding desmopressin (DDAVP) is a therapeutic option and the “off label” use of recombinant activated factorVIIa (rFVIIa) remains an option for individual situations with stringent indications and when the above named measures to optimize the coagulation situation have been taken.
    Der Anaesthesist 10/2009; 58(10):1010-1026. DOI:10.1007/s00101-009-1595-z · 0.74 Impact Factor
Show more